Combination chemotherapy with VM-26, adriamycin, bleomycin, and prednisone as a secondary treatment of malignant lymphoma

A. Goldhirsch, M. Pirovino, R. W. Sonntag, L. Tschopp, H. J. Ryssel, K. W. Brunner

Research output: Contribution to journalArticle

Abstract

Thirty-eight pretreated patients with Hodgkin's disease (HD) and malignant non-Hodgkin's lymphoma were given combination chemotherapy with VM-26, Adriamycin, bleomycin, and prednisone. Four of 15 evaluable patients with HD achieved a partial remission (PR), with a median duration of 8 months. Of 12 patients with diffuse poorly differentiated lymphocytic lymphoma, one achieved a complete remission (30+ months) and five achieved a PR (median, 6 months). One of three patients with histiocytic lymphoma had a PR of 1.5 months. There was one drug-related death. Five patients developed life-threatening hematologic toxicity. Two HD responders died of acute nonlymphocytic leukemia.

Original languageEnglish
Pages (from-to)335-337
Number of pages3
JournalCancer Treatment Reports
Volume64
Issue number2-3
Publication statusPublished - 1980

Fingerprint

Teniposide
Bleomycin
Prednisone
Combination Drug Therapy
Doxorubicin
Lymphoma
Hodgkin Disease
Therapeutics
Mantle-Cell Lymphoma
Lymphoma, Large B-Cell, Diffuse
Acute Myeloid Leukemia
Non-Hodgkin's Lymphoma
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Goldhirsch, A., Pirovino, M., Sonntag, R. W., Tschopp, L., Ryssel, H. J., & Brunner, K. W. (1980). Combination chemotherapy with VM-26, adriamycin, bleomycin, and prednisone as a secondary treatment of malignant lymphoma. Cancer Treatment Reports, 64(2-3), 335-337.

Combination chemotherapy with VM-26, adriamycin, bleomycin, and prednisone as a secondary treatment of malignant lymphoma. / Goldhirsch, A.; Pirovino, M.; Sonntag, R. W.; Tschopp, L.; Ryssel, H. J.; Brunner, K. W.

In: Cancer Treatment Reports, Vol. 64, No. 2-3, 1980, p. 335-337.

Research output: Contribution to journalArticle

Goldhirsch, A, Pirovino, M, Sonntag, RW, Tschopp, L, Ryssel, HJ & Brunner, KW 1980, 'Combination chemotherapy with VM-26, adriamycin, bleomycin, and prednisone as a secondary treatment of malignant lymphoma', Cancer Treatment Reports, vol. 64, no. 2-3, pp. 335-337.
Goldhirsch, A. ; Pirovino, M. ; Sonntag, R. W. ; Tschopp, L. ; Ryssel, H. J. ; Brunner, K. W. / Combination chemotherapy with VM-26, adriamycin, bleomycin, and prednisone as a secondary treatment of malignant lymphoma. In: Cancer Treatment Reports. 1980 ; Vol. 64, No. 2-3. pp. 335-337.
@article{d135a401963a40d8a65b2e275623c379,
title = "Combination chemotherapy with VM-26, adriamycin, bleomycin, and prednisone as a secondary treatment of malignant lymphoma",
abstract = "Thirty-eight pretreated patients with Hodgkin's disease (HD) and malignant non-Hodgkin's lymphoma were given combination chemotherapy with VM-26, Adriamycin, bleomycin, and prednisone. Four of 15 evaluable patients with HD achieved a partial remission (PR), with a median duration of 8 months. Of 12 patients with diffuse poorly differentiated lymphocytic lymphoma, one achieved a complete remission (30+ months) and five achieved a PR (median, 6 months). One of three patients with histiocytic lymphoma had a PR of 1.5 months. There was one drug-related death. Five patients developed life-threatening hematologic toxicity. Two HD responders died of acute nonlymphocytic leukemia.",
author = "A. Goldhirsch and M. Pirovino and Sonntag, {R. W.} and L. Tschopp and Ryssel, {H. J.} and Brunner, {K. W.}",
year = "1980",
language = "English",
volume = "64",
pages = "335--337",
journal = "Cancer Treatment Reports",
issn = "0361-5960",
publisher = "U.S. National Cancer Institute",
number = "2-3",

}

TY - JOUR

T1 - Combination chemotherapy with VM-26, adriamycin, bleomycin, and prednisone as a secondary treatment of malignant lymphoma

AU - Goldhirsch, A.

AU - Pirovino, M.

AU - Sonntag, R. W.

AU - Tschopp, L.

AU - Ryssel, H. J.

AU - Brunner, K. W.

PY - 1980

Y1 - 1980

N2 - Thirty-eight pretreated patients with Hodgkin's disease (HD) and malignant non-Hodgkin's lymphoma were given combination chemotherapy with VM-26, Adriamycin, bleomycin, and prednisone. Four of 15 evaluable patients with HD achieved a partial remission (PR), with a median duration of 8 months. Of 12 patients with diffuse poorly differentiated lymphocytic lymphoma, one achieved a complete remission (30+ months) and five achieved a PR (median, 6 months). One of three patients with histiocytic lymphoma had a PR of 1.5 months. There was one drug-related death. Five patients developed life-threatening hematologic toxicity. Two HD responders died of acute nonlymphocytic leukemia.

AB - Thirty-eight pretreated patients with Hodgkin's disease (HD) and malignant non-Hodgkin's lymphoma were given combination chemotherapy with VM-26, Adriamycin, bleomycin, and prednisone. Four of 15 evaluable patients with HD achieved a partial remission (PR), with a median duration of 8 months. Of 12 patients with diffuse poorly differentiated lymphocytic lymphoma, one achieved a complete remission (30+ months) and five achieved a PR (median, 6 months). One of three patients with histiocytic lymphoma had a PR of 1.5 months. There was one drug-related death. Five patients developed life-threatening hematologic toxicity. Two HD responders died of acute nonlymphocytic leukemia.

UR - http://www.scopus.com/inward/record.url?scp=0018851047&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018851047&partnerID=8YFLogxK

M3 - Article

C2 - 6157468

AN - SCOPUS:0018851047

VL - 64

SP - 335

EP - 337

JO - Cancer Treatment Reports

JF - Cancer Treatment Reports

SN - 0361-5960

IS - 2-3

ER -